Guanze Medical published its Environmental, Social and Governance (ESG) Report for the year ended 31 December 2025, detailing material progress in sustainability governance, environmental performance and social indicators across its mainland China operations.
Governance Structure and Certifications • The board retains ultimate oversight of ESG strategy, supported by an ESG working group comprising senior department heads. • Climate-related risks are integrated into the enterprise risk management framework and reviewed annually by the board’s audit committee. • New and renewed management accreditations obtained during the year include ISO 14001:2015 (environment), ISO 45001:2018 (occupational health & safety), ISO 9001:2015 (quality), ISO 13485:2016 (medical device quality), ISO 20000-1:2018 (IT service) and ISO 27001:2022 (information security).
Environmental Metrics (FY 2025) • Total greenhouse-gas (GHG) emissions: 833.31 tonnes of CO₂e, comprising 77.02 t (Scope 1), 15.52 t (Scope 2, location-based) and 740.77 t (Scope 3). Scope 3 disclosure was expanded to cover four categories for the first time. • Energy consumption: 313,132.39 kWh, mainly from diesel (165,172.45 kWh), petrol (122,527.94 kWh) and purchased electricity (25,432.00 kWh). • Atmospheric pollutants: SOx 0.43 kg, NOx 108.47 kg, PM 10.28 kg. • Waste: no hazardous waste generated; non-hazardous waste totalled 1.60 tonnes. • Emission targets include full regulatory compliance and maintenance of waste generation within ±10% of 2024 levels over the next three years.
Decarbonisation Roadmap • Intensity-based reduction targets call for a 5% cut in key environmental indicators by 2030 versus the 2025 baseline, with specific goals to trim energy-use and combined Scope 1-2 GHG intensities by 2%. • Scenario analysis, aligned with IPCC SSP and NGFS pathways, indicates low physical-risk exposure and moderate transition-risk exposure, particularly under accelerated decarbonisation policies. • Capital expenditure linked to climate-related mitigation or adaptation is expected to be limited; however, regular reviews will update targets and transition plans.
Social Performance • Workforce: 55 employees (43 male, 12 female); average tenure exceeds four years. • Turnover rate: 24% in mainland China; no work-related injuries or fatalities during 2025. • Training: 100% employee coverage; average 19.27 training hours per employee. • Supply chain: 70 domestic suppliers evaluated annually for quality, environmental and social compliance. • Product responsibility: zero product recalls, zero customer complaints and continuous quality oversight via certified management systems. • Governance: no corruption cases recorded; anti-bribery and whistle-blowing mechanisms in place.
Outlook Guanze Medical plans to deepen Scope 3 data coverage, enhance supplier environmental screening and align future disclosures with evolving Hong Kong Stock Exchange requirements, underpinning its commitment to consistent ESG improvement and contribution to national “dual-carbon” goals.